Memantine Vipharm (Memantine Hydrochloride)

Memantine binds to the ion channel of the NMDA receptor with low to moderate affinity, blocking excessive calcium influx caused by overstimulation with glutamate. This neuroprotective action reduces excitotoxic neuronal injury while allowing normal synaptic activity essential for learning and memory.

The appropriate dose of Memantine Vipharm is determined by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. Dosage regimens are individualized and should follow local prescribing guidelines.

Safety data for memantine in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To request Memantine Vipharm, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Memantine belongs to the NMDA receptor antagonist class, whereas other approved agents such as cholinesterase inhibitors (e.g., donepezil) target acetylcholine metabolism. Memantine is often used in moderate to severe disease and may be combined with a cholinesterase inhibitor for additive benefit, while having a distinct side‑effect profile.

Memantine Vipharm should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, heat, and direct sunlight to maintain stability and potency throughout its shelf life.

Memantine Vipharm is taken orally, usually as a tablet, with or without food. The exact administration schedule—such as once daily or divided doses—should follow the prescriber’s instructions and may be adjusted based on tolerability and clinical response.

Serious adverse events, although uncommon, include seizures, severe hypertension, hallucinations or psychosis, and allergic skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored for these symptoms, and therapy should be discontinued if any serious reaction occurs.

Memantine Vipharm is contraindicated in patients with known hypersensitivity to memantine or any excipients in the formulation. Caution is advised for individuals with severe renal impairment, uncontrolled hypertension, a history of seizures, or those taking other NMDA antagonists.